Online inquiry

IVTScrip™ mRNA-Anti-TNF, PEG sTNF-RI(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12992MR)

This product GTTS-WQ12992MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, PEG sTNF-RI(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ12992MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1745MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ADCT-301
GTTS-WQ7417MR IVTScrip™ mRNA-Anti-EGFR, GA201(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA GA201
GTTS-WQ367MR IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 20A11-9mer-ALB11
GTTS-WQ12125MR IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MORAb-003
GTTS-WQ15422MR IVTScrip™ mRNA-Anti-LAG3, TSR-033(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA TSR-033
GTTS-WQ1550MR IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ACE-041
GTTS-WQ8778MR IVTScrip™ mRNA-Anti-PCSK9, IBI-306(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA IBI-306
GTTS-WQ10905MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MABp1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW